Scotiabank downgraded Blueprint Medicines (BPMC) to Sector Perform from Outperform with a $135 price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Hold from Buy at Needham
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Blueprint Medicines downgraded to Neutral from Outperform at Wedbush
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
- Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila